Skip to main content

Table 5 Cumulative number of days of systemic symptoms during intervention period

From: Efficacy of heat-killed Lactococcus lactis JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial

   1, 2, 3 4, 5 p valuea
Physical condition (n) Placebo 184 125 0.030
 (1: Very bad, 2: Bad, 3: Normal, 4: Good, 5: Very good) LC-Plasmab 171 166  
Fatigue (n) Placebo 128 182 0.032
 (1: Severe, 2: Moderate, 3: Mild, 4: Slight, 5: Normal) LC-Plasmac 110 225  
Articular pain (n) Placebo 16 294 0.016
 (1: Severe, 2: Moderate, 3: Mild, 4: Slight, 5: Normal) LC-Plasmad 5 332  
Chill (n) Placebo 2 308 0.516
 (1: Severe, 2: Moderate, 3: Mild, 4: Slight, 5: Normal) LC-Plasma 5 332  
Lassitude (n) Placebo 52 258 0.098
 (1: Severe, 2: Moderate, 3: Mild, 4: Slight, 5: Normal) LC-Plasma 75 262  
Muscle pain (n) Placebo 62 248 1.000
 (1: Severe, 2: Moderate, 3: Mild, 4: Slight, 5: Normal) LC-Plasma 68 268  
  1. The cumulative number of days of each symptom was counted separately
  2. aThe cumulative days of each symptoms were compared between the placebo and LC-Plasma groups by Chi-square test
  3. bThe adjusted residual of the LC-Plasma group [4, 5] was calculated as 2.2
  4. cThe adjusted residual of the LC-Plasma group [4, 5] was calculated as 2.2
  5. dThe adjusted residual of the LC-Plasma group [4, 5] was calculated as 2.6